Drug Trial Radar · NCT05844982
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Nov 21, 2023
Primary completion
Dec 26, 2029
Study completion Dec 26, 2029
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI); National Institutes of Health (NIH); Alimera Sciences; Genentech, Inc.
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Conditions
- Radiation Retinopathy
- Visual Impairment
Interventions
FaricimabDrug
6.0 mg intravitreal injection at randomization and every 3 months
fluocinolone acetonideDrug
0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in visual acuity from baselineTime frame: from baseline at 3 years
- Loss of 15 or more letters of visual acuity from baselineTime frame: from baseline at 3 years
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Byers Eye Institute at Stanford University
Palo Alto, California · Recruiting
Retina Consultants
Manchester, Connecticut · Recruiting
Retina Associates of Florida, LLC
Tampa, Florida · Recruiting
Emory Eye Center
Atlanta, Georgia · Recruiting
Northwestern Memorial Group
Chicago, Illinois · Recruiting
IL Eye and Ear Infirmary-University of Illinois at Chicago
Chicago, Illinois · Recruiting
Midwest Eye Institute
Indianapolis, Indiana · Recruiting
University of Iowa Department of Ophthalmology and Visual Sciences
Iowa City, Iowa · Recruiting
University of Kentucky Advanced Eye Care
Lexington, Kentucky · Recruiting
Massachusetts Eye and Ear
Boston, Massachusetts · Recruiting
Foundation for Vision Research and Retina Specialists of Michigan, P.C.
Grand Rapids, Michigan · Recruiting
Associated Retinal Consultants, P.C.
Royal Oak, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University Ophthalmology
St Louis, Missouri · Recruiting
Retina Research Institute, LLC
St Louis, Missouri · Recruiting
Duke Eye Center
Durham, North Carolina · Recruiting
The Cleveland Clinic Foundation DBA Cleveland Clinic Lerner College of Medicine
Celveland, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Retina-Vitreous Consultants, Inc.
Monroeville, Pennsylvania · Recruiting
Wills Eye Hospital
Philadelphia, Pennsylvania · Recruiting
Pittsburgh Clinical Trial Consortium
Sewickley, Pennsylvania · Recruiting
Retina Consultants of Carolina, PA
Greenville, South Carolina · Recruiting
Southeastern Retina Associates
Hixson, Tennessee · Recruiting
Tennessee Retina, PC
Nashville, Tennessee · Recruiting
Retina Consultants of Texas, PA
Bellaire, Texas · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Eye Cancer Associates of Texas
Houston, Texas · Recruiting
Texas Retina Associates
Lubbock, Texas · Recruiting
The Board of Regents of the University of Wisconsin System
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.